Evidence map›Paper›PMID 21844907›Full record

ReviewNature reviews. Endocrinology2011

The G-protein-coupled estrogen receptor GPER in health and disease.

Eric R Prossnitz, Matthias Barton

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 432 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
432citing papers in PubMed, 1 pooled it
32.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

432 citing papers in PubMed, 1 synthesis or guideline pooled it, 892 citations in OpenAlex.

  1. Pooled it
  2. Physiological 17β-oestradiol inhibits KChannels (Austin, Tex.) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

372 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Eric R ProssnitzDepartment of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA. eprossnitz@salud.unm.edu
Matthias Barton
University of New Mexico · USUniversity of Zurich · CH

Funding

Development of GPR30-Selective LigandsR01CA127731 · NCI · UNIVERSITY OF NEW MEXICO · PI ARTERBURN, JEFFREY B, OPREA, TUDOR I · 2008 to 2012
$1.7M
A novel intracellular 7TM estrogen receptor in breastR01CA116662 · NCI · UNIVERSITY OF NEW MEXICO · PI PROSSNITZ, ERIC R · 2006 to 2010
$1.3M
The Role of GPR30 in Advanced Endometrial CancerR01CA118743 · NCI · UNIVERSITY OF NEW MEXICO · PI PROSSNITZ, ERIC R · 2007 to 2009
$855k
NCI NIH HHS CA116662NCI NIH HHS CA118743NCI NIH HHS CA127731NCI NIH HHS R01 CA116662NCI NIH HHS R01 CA118743NCI NIH HHS R01 CA127731
6 · The paper itself

Abstract

Estrogens mediate profound effects throughout the body and regulate physiological and pathological processes in both women and men. The low prevalence of many diseases in premenopausal women is attributed to the presence of 17β-estradiol, the predominant and most potent endogenous estrogen. In addition to endogenous estrogens, several man-made and plant-derived molecules, such as bisphenol A and genistein, also exhibit estrogenic activity. Traditionally, the actions of 17β-estradiol are ascribed to two nuclear estrogen receptors (ERs), ERα and ERβ, which function as ligand-activated transcription factors. However, 17β-estradiol also mediates rapid signaling events via pathways that involve transmembrane ERs, such as G-protein-coupled ER 1 (GPER; formerly known as GPR30). In the past 10 years, GPER has been implicated in both rapid signaling and transcriptional regulation. With the discovery of GPER-selective ligands that can selectively modulate GPER function in vitro and in preclinical studies and with the use of Gper knockout mice, many more potential roles for GPER are being elucidated. This Review highlights the physiological roles of GPER in the reproductive, nervous, endocrine, immune and cardiovascular systems, as well as its pathological roles in a diverse array of disorders including cancer, for which GPER is emerging as a novel therapeutic target and prognostic indicator.

Indexed as

AnimalsBenzhydryl CompoundsBisphenol A CompoundsCardiovascular SystemEndocrine SystemEstradiolFemaleGenisteinHumansImmune SystemMaleNeoplasmsNervous SystemPhenolsPremenopauseReceptors, EstrogenBenzhydryl Compoundsbisphenol ABisphenol A CompoundsEstradiolGenisteinPhenolsReceptors, EstrogenReceptors, G-Protein-Coupled

Identifiers

PMID21844907
PMCPMC3474542
OpenAlexW2075443461

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.